Table 2.

Summary of adverse events per MedDRA preferred term (≥ 30% of patients for any adverse events or ≥ 5% treatment-related adverse events)

Patients with an AE, n (%) N = 26	All AEs		Treatment-related AEs
	Any grade	Grade ≥ 3	Any grade	Grade ≥ 3
Nausea	15 (57.7)	0	13 (50.0)	3 (11.5)
Decreased appetite	14 (53.8)	0	8 (30.8)	0
Febrile neutropenia	14 (53.8)	14 (53.8)	3 (11.5)	0
Hypomagnesemia	13 (50.0)	0	1 (3.8)	0
Diarrhea	13 (50.0)	1 (3.8)	13 (50.0)	1 (3.8)
Hypokalemia	11 (42.3)	6 (23.1)	0	0
Vomiting	10 (38.5)	0	9 (34.6)	0
Constipation	10 (38.5)	0	0	0
Fatigue	10 (38.5)	1 (3.8)	7 (26.9)	1 (3.8)
Stomatitis	9 (34.6)	3 (11.5)	5 (19.2)	1 (3.8)
Hypotension	9 (34.6)	0	0	0
Edema peripheral	9 (34.6)	0	1 (3.8)	0
Hypophosphatemia	8 (30.8)	3 (11.5)	0	0
Hyperphosphatemia	8 (30.8)	0	0	0
Abdominal pain	8 (30.8)	1 (3.8)	5 (19.2)	0
Epistaxis	5 (19.2)	2 (7.7)	3 (11.5)	2 (7.7)
Dyspepsia	4 (15.4)	0	2 (7.7)	0
Alopecia	4 (15.4)	0	4 (15.4)	0

AE adverse event, MedDRA Medical Dictionary for Regulatory Activities